4.1 Review

Cardiac Hypertrophy and Fibrosis in the Metabolic Syndrome: A Role for Aldosterone and the Mineralocorticoid Receptor

Journal

INTERNATIONAL JOURNAL OF HYPERTENSION
Volume 2011, Issue -, Pages -

Publisher

HINDAWI LTD
DOI: 10.4061/2011/346985

Keywords

-

Funding

  1. National Institutes of Health (NIH) [T32HL007224]
  2. NIH [HL079099, HL095891, HL102631]
  3. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL102631, R01HL079099, T32HL007224, R21HL095891] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Obesity and hypertension, major risk factors for the metabolic syndrome, render individuals susceptible to an increased risk of cardiovascular complications, such as adverse cardiac remodeling and heart failure. There has been much investigation into the role that an increase in the renin-angiotensin-aldosterone system (RAAS) plays in the pathogenesis of metabolic syndrome and in particular, how aldosterone mediates left ventricular hypertrophy and increased cardiac fibrosis via its interaction with the mineralocorticoid receptor (MR). Here, we review the pertinent findings that link obesity with elevated aldosterone and the development of cardiac hypertrophy and fibrosis associated with the metabolic syndrome. These studies illustrate a complex crosstalk between adipose tissue, the heart, and the adrenal cortex. Furthermore, we discuss findings from our laboratory that suggest that cardiac hypertrophy and fibrosis in the metabolic syndrome may involve cross-talk between aldosterone and adipokines (such as adiponectin).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available